Employing Murine MAbs as Ancillary Products in Cell Therapy Manufacturing, Part 2, A Case Study

November 15, 2001
Steven Ford

,
William E. Tente

BioPharm International, BioPharm International-11-01-2001, Volume 14, Issue 11

by Steven Ford and William E. Tente Chimeric Therapies, Inc. Experience shows that murine MAbs used in cell therapy manufacturing can be produced with safety concerns in mind. In such cases, adequate characterization ensures that they retain functional integrity.